Kinase Chemistry – Just a year and a half behind the times.

Clinical Roundup

Posted by kinasepro on October 9, 2007

Pharmacopoeia – earned a milestone for p38 inhibitor BMS-582949 going ph2.

Incyte – reported on ph2 Jak inhibitor INCB-18424 (?WO/2005/105814, 2B7A) (decent webcast here The short of it: pretty much the same as steroids … no adverse effects at any dose. check in ~8 minutes).

Exelixis – will bundle reports for ph2 XL-880, XL-647, and ph1 XL-184, XL820, and XL-147 at AACR later this month. The Fools think GSK will pick up 880 and I tend to agree.

Ambit talked about a lot at UBS and updates on AC-220 (ph1 FLT3 inhibitor).

Ardea (RDEA)- is preparing to list on the Nasdaq and has RDEA-119 about to hit ph1.

SGX – spins a yarn suggesting that Novartis took a pass on SGX-393. IND for a different compound expected mid ’08. (Webcast on Thursday)

Ariad – knows all about T315I and SGX… Still no structure for AP-24534 though… IND expected end of the year.

S*Bio – has SB-1518 an oral Jak2 (V617F) inhibitor in development: WO/2007/058628, WO/2007/058627

2 Responses to “Clinical Roundup”

  1. milkshake said

    I liked the previous theme better – the font was a lot esier to read.

  2. kinasepro said

    I like what TM did… Looking for something different but I’m not thrilled with any of them.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: